Table 1 Subject baseline co-variates by ELN criteria.
From: Is there really an accelerated phase of chronic myeloid leukaemia at presentation?
CP (n = 1837) | AP (n = 285) | P-value | |
|---|---|---|---|
Age, years, median (Interquartile range, IQR) | 40 (30, 52) | 42 (31, 54) | 0.06 |
Male, n (%) | 1133 (62) | 181 (64) | 0.58 |
ELTS risk score, n (%) | |||
Low | 1209 (66) | ||
Intermediate | 453 (25) | ||
High | 175 (10) | ||
AP criteria, n (%) | |||
Basophils >20% | 204 (71) | ||
Blasts ≥15% and <30% | 37 (13) | ||
Platelets <100 × 10E + 9/L | 31 (11) | ||
≥2 criteria | 13 (5) | ||
1st TKI-therapy | <0.001 | ||
Imatinib | 1452 (79) | 188 (66) | |
2G-TKI | 385 (21) | 97 (34) | |
Types of 2G-TKIS, n (%) | |||
Nilotinib | 257 (67) | 68 (70) | |
Dasatinib | 63 (16) | 21 (22) | |
Flumatinib | 51 (13) | 8 (8) | |
Radotinib | 15 (4) | 0 (0) | |
Follow-up, months, median (IQR) | 53 (27, 84) | 49 (25, 96) | 0.97 |
